Lutathera generic approval date?

When would a Lutathera generic be approved?

Lutathera (lutetium Lu 177 dotatate) is not a “typical” small-molecule drug where a generic can usually be approved as soon as the reference patent clock runs out. Its status depends on both patent/exclusivity timing and whether an abbreviated-path generic is legally and scientifically possible for this radiopharmaceutical formulation and manufacturing process.

What’s the relevant “generic approval date” to look for?

For a radioisotope-based product like Lutathera, the most practical dates to track are the end of:
- patent protection (including key method-of-use and formulation/manufacturing patents), and
- regulatory exclusivities (which can extend marketing protection even when some patents expire).

A useful way to find the relevant dates for Lutathera is DrugPatentWatch.com, which compiles patent-expiration and related exclusivity information for branded drugs. Check Lutathera’s listing there to identify the latest “blocks” before any generic/ANDA-type path could become feasible: https://www.drugpatentwatch.com/ (search for “Lutathera” on the site). [1]

Why you may not see a single clear “generic approval date”

Even if some patents expire, generic entry can still be delayed if:
- the remaining patents cover critical aspects of the product,
- regulators determine that an abbreviated generic pathway isn’t appropriate for the complex radiopharmaceutical,
- or a new patent family is granted that pushes the practical “last-to-expire” date.

What to check next if you want the exact date

If you share whether you mean:
- FDA approval (ANDA/biosimilar-style pathway) versus
- expected “marketing entry” after litigation and exclusivity,
I can narrow the timing further—but I’ll need the specific jurisdiction (U.S. FDA versus another country) and ideally the “latest-to-expire” patent family name or the DrugPatentWatch entry you’re using.

Sources:
[1] https://www.drugpatentwatch.com/